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Introduction 
Glucocorticoids (GCs) are the most effective treatment of 
asthma. They have been used orally in asthma for more 
than 40 yr and by inhalation for over 20 yr. Although we do 
have this long experience with these compounds, many key 
issues concerning their proper place in the management of 
asthma still remain a matter of some uncertainty. The 
recognition of asthma as an inflammatory disease has led to 
a change in treatment strategy for this disease. Inhaled GCs 
for example have been the recommendation of recent major 
consensus panels with the goal being the prevention of 
asthma symptoms in patients with moderate and severe 
chronic asthma (Table 1) (1). 
In this paper, we will analyse the available data on GC 
pharmacology in order to address some of the following 
questions. (1) What are the main clinical and biological 
targets of GC? (2) When and with which route to use GC in 
acute asthma? (3) What is the amount of GC required to 
induce a remission in acute and chronic asthma? (4) Does 
one GC provide major therapeutic advantage over others? 
(5) How should GC therapy be scheduled during the day to 
optimize the treatment? (6) How long should we use GCs in 
the treatment of both acute and chronic asthma? (7) Why 
are GCs orally needed in GC-dependent patients and how 
to manage these patients? (8) What is GC resistance? (8) 
Should every asthmatic be started on inhaled GC therapy? 
(9) What are the long-term beneficial deleterious effects of 
GC? 
General Principles of Corticosteroids in 
Asthma 
WHAT ARE THE MAIN CLINICAL AND 
BIOLOGICAL TARGETS OF GCs? 
GCs are beneficial in controlling asthma symptoms, 
reducing asthma exacerbations and hospitalizations, mini- 
mizing &agonist consumption, improving baseline FEV, 
and decreasing (but not completely normalizing) bronchial 
hyperresponsiveness. GCs block the late-phase reaction 
following allergen provocation. GCs act upstream to 
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multiple inflammatory pathways characterizing asthma 
and this may explain why they would be more effective 
than therapies that target at only a single mediator or 
cytokine level. Recent biopsy and bronchoalveolar lavage 
studies have given insights into their cellular mechanisms 
of action (2-8). These well-designed studies concerned 
mostly short-term and medium-term effects of GCs. Long- 
term effects remain very seldom examined. The most 
striking evidence of GC action in asthma is the reduction 
of the cellular inflammatory infiltrate, with no or little 
effect on the increased thickening of the basal membrane. 
The reduction of bronchoalveolar eosinophil, T-cell and 
mast cell numbers during GC treatment is mainly due to 
the inhibition of the synthesis of chemotactic and activat- 
ing inflammatory mediators such as cytokines. Thus, 
Robinson et al. have (6) found that after 2 weeks of 
0.6 mg kg- ’ of prednisolone in 18 patients that Th2 cells 
(expressing IL-4 and IL-5 mRNA) decreased. Laitinen 
et al. (3) have found that, after 16 weeks of inhaled 
budesonide, mast cell and eosinophil numbers decreased 
within the bronchi, although T-cell number remained 
unchanged in this study. Lundgren et al. (4) have shown 
in six severe asthmatics treated for 10 yr with daily 6OOS 
8OOpg budesonide that T-cells and plasma cells within the 
airways decreased dramatically, although the eosinophils 
may persist in some patients, as observed by Booth et al. 
(5) after 3 months of inhaled fluticasone. It is clear that 
GCs do no necessarily reverse all the abnormalities of 
asthma, and the subepithelial fibrosis in particular. The 
exact mechanisms of action of GCs in asthma are, 
however, unknown (2,7). 
Although T cells and GC receptors are the best 
candidates for GC action, a role for other cell types and 
transcription factors cannot be ruled out. Thus, the basic 
mechanisms of GC actions include activation of the intra- 
cellular GC receptor followed by binding of the receptor 
to specific DNA sites in the nucleus to regulate transcrip- 
tion of target genes (Fig. 1). Abnormal GC receptor 
binding to the GCs and to their specific DNA responsive 
element has been found in the peripheral blood T cells of 
GC-resistant patients (7). More recently, it has been 
recognized that GC-GC receptor complex interacts with 
transcription factors such as NFKB and AP-1, and this is 
likely to be a major mechanism by which GCs inhibit the 
transcription of several pro-inflammatory cytokines and 
chemokines in asthma. The airway epithelium could,,also 
be an important site of action of topical GCs, as it 
expresses many cytokines such as GM-CSF, MCP-1 and 
0 1998 W. B. SAUNDERS COMPANY LTD 
386 TOPICAL REVIEWS 
TABLE 1. Classification of asthma severity adapted from the recent guidelines (1) 
Asthma Clinical features 
severity before treatment Lung function 
Regular medication required 
to maintain control 
Intermittent 0 Brief symptoms ~1 time 
per week 
0 Nocturnal asthma 
symptoms <2 times per 
month 
0 Asymptomatic between 
exacerbations 
0 No limitation of everyday 
activities, no loss of work 
or schooling 
Mild 
persistent 
0 Exacerbations >l time per 
week 
0 Nocturnal asthma 
symptoms >2 times per 
month 
Moderate 
persistent 
0 Exacerbations >2 times per 
week 
0 Nocturnal asthma 
symptoms >l time per 
week 
0 Symptoms requiring 
&agonists almost daily 
Severe 
persistent 
0 Frequent exacerbations 
0 Frequent nocturnal asthma 
0 Continuous symptoms 
0 Physical activities limited 
0 Hospitalization for asthma 
0 PEF and FEV, 280% 
predicted or personal best 
value at baseline 
0 PEF variability* <20% 
0 PEF and FEV, 280% 
predicted or personal best 
value at baseline 
0 PEF variability* 20-30% 
0 PEF and FEV, 60-80% 
predicted or personal best 
value at baseline 
l PEF variability* ~30% 
0 PEF and FEV, ~60% 
predicted or personal best 
value at baseline 
0 PEF variability* >30% 
Occasional need for 
short-acting j&-agonists 
(less than 1 time per week) 
Inhaled daily GC (children 
begin with a trial of 
cromolyn) 
Long-acting &agonists 
may be needed (particularly 
for nocturnal asthma) 
Short-acting &agonists (as 
needed if sufficient); 
consider theophylline 
Inhaled daily GC (children 
begin with a trial of 
cromolyn) 
Long-acting &agonists 
may be needed (particularly 
for nocturnal asthma 
Short-acting j&-agonists (as 
needed if sufficient); 
consider theophylline 
Inhaled daily high dose of 
GC 
Long-acting &agonists 
Frequent use of oral GCs 
Short-acting &agonists 
Consider theophyllines 
Asthma severity may by clinically and functionally assessed over the previous 12 months by taking a careful history from the 
asthmatics (including frequency and severity of symptoms and their response to treatment) and by measuring airway 
obstruction by spirometry and ambulatory monitoring of PEF. 
*PEF variability= [(evening PEF - morning PEF)/(evening PEF +moming PEF)] x l/2. 
RANTES, in addition to GC receptors. Thus, topical 
steroids inhibit the expression of these cytokines in the 
Corticosteroids in Acute Severe Asthma 
airway epithelium. Increased AP-1 has been observed also 
in asthmatic epithelium (9). In acute severe asthma, other 
effects of GCs include inhibition of airway microvascular 
leakage and oedema and increased expression of 
&adreneric receptors which may lead to increase efficacy 
of inhaled &agonists. 
WHEN, HOW MUCH AND WITH WHICH 
ROUTE TO USE GCs IN ACUTE ASTHMA? 
In acute severe asthma, which does not respond to bron- 
chodilators, GCs should be used early and systematically. 
This is known to shorten the course of asthma, to prevent 
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FIG. 1. Diagrammatic representation of the action of glucocorticoids (GCs) in inhibiting gene transcription of many 
proteins such as enzymes, receptors and cytokines in asthma. An increase in certain regulatory transcription factors such 
as activator protein-l (AP-1) or nuclear factor rcB (NFKB) through cytokine-receptor activation [e.g. by tumour necrosis 
factor a (TNF-a)] may occur in asthma. GCs penetrate into the cell and bind to glucocorticoid receptor (GR) which 
immediately translates to the nucleus to bind to glucocorticoid response elements (GRE). However, one of the main 
effects of the activated GR is to interact directly with transcription factors such as AP-1 and NFKB, thus preventing their 
binding to their DNA binding sites (e.g. TRE and K-B respectively). This would in turn lead to a reduction or suppres- 
sion of transcription of several protein genes. Many inducible cytokine genes do not have a regulatory GRE sequence on 
their promoter region and, therefore, the main effect of GCs would be to prevent binding of transcription factors to 
DNA. (Reproduced by permission of Dr I. Adcock.) 
relapses and to reduce hospitalization rates, especially in 
patients with high risk of fatal asthma (10). In ambulatory 
patients, the optimal dose and schedule of administration 
have not been defined and controlled trials are needed. In 
adults, it is usual to administer orally 0.5-l mg kg- ’ 
day- ’ of short-acting GCs (e.g. prednisolone) (10). 
Patients requiring hospitalization may require higher doses 
of GCs, although some investigators have not found any 
advantage from using high doses administered intra- 
venously (e.g. 1 versus 6 mg kg - ’ day ~ ’ of IV methyl- 
prednisolone) (10,ll). In one study, there was no apparent 
advantage of using intravenous hydrocortisone compared 
with oral prednisolone in acute severe asthmatic patients 
not in respiratory failure (12). 
DOES ONE GC PROVIDE MAJOR 
THERAPEUTIC ADVANTAGE OVER OTHERS? 
Most of the available GCs have been used in the treatment 
of acute severe asthma and there are no data suggesting 
that one compound is better than another at comparable 
doses (10). There are, however, differences in side-effects 
and costs. Thus, methylprednisolone, because of its greater 
anti-inflammatory potency, its lower mineralocorticoid 
activity and its lower price by comparison with hydro- 
cortisone, may be the drug of choice for intravenous 
therapy (10). Moreover, there is some evidence that 
methylprednisone is distributed better into the lungs than 
prednisone (13) and prednisolone (14) (Table 2). Concern- 
ing the use of prodrugs such as cortisone and prednisone, 
which need to be hydroxylated in the liver to become active, 
there is no evidence that, in the absence of liver disease, 
these compounds are any less effective than prednisolone or 
methylprednisolone, which are active per se (10). A high 
dose of intramuscular triamcinolone was found to be more 
effective than oral prednisone in terms of improved lung 
function, reduction in emergency room visits and hospital- 
izations, but steroid side-effects were greater with triamci- 
nolone acetonide (15). However, optimal dosage and mode 
of administration need to be defined with triamcinolone. 
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HOW SHOULD GC THERAPY BE SCHEDULED 
DURING THE DAY AND FOR HOW LONG IN 
THE OPTIMIZATION OF THE TREATMENT IN 
ACUTE SEVERE ASTHMA? 
Systemic GC should be continued at least until symptoms 
are controlled and pulmonary function is stably restored to 
the patient’s normal or best value. Both overtreating and 
undertreating asthma may be harmful, because of either 
side-effects or relapse of uncontrolled asthma. In acute 
asthma, one would assume that overtreating is not a 
critical issue (because of the shortness of the GC course) 
although undertreating may lead to relapse of asthma 
attack. Clinicians may need markers to set the right level of 
treatment. However, such markers do not exist even if 
Skedinger et al. (16) have recently shown in nine patients 
experiencing an asthma exacerbation that the percentage of 
blood eosinophils, the serum and intracellular eosinophil 
cationic protein (ECP) decreased significantly after 7-9 
days of oral prednisolone (starting with 30mg daily). 
These markers did not correlate with each other or with 
clinical parameters. The results of this study should be 
compared with those of Wever et al. (17) who found in 20 
symptomatic patients followed for 6 months and monitored 
once monthly (and during exacerbations) that there was a 
correlation between serum ECP and FEV,. Thus, duration 
of treatment and a tapering schedule are very common 
practice and must be individualized on the basis of the 
severity of the asthma exacerbation and the patient’s 
previous history. After a short treatment course (1 week), 
GCs can be stopped abruptly as there is no evidence 
of hypothalamic-pituitary-adrenocortical suppression. 
Longer courses may require gradual dose reduction to 
allow adrenal recovery. On the other hand, gradual dose 
reduction is also necessary in more severe patients to avoid 
rebound asthma and other drugs (high-dose inhaled GCs in 
particular) may be used during this period. 
Oral Corticosteroids in Chronic Asthma 
GC-DEPENDENT ASTHMA: WHY AND HOW 
TO MANAGE? 
Most asthmatic patients are well controlled by inhaled 
medications. Although GCs are usually given by inhalation, 
it is necessary to give them orally in some patients (so called 
GC-dependent asthmatics). This patient group is very 
heterogeneous, some being stable with a subnormal lung 
function and a GC dose requirement around 10 mg daily, 
others being unstable although they are taking high dose 
of GC every day (18). There is so far no apparent evi- 
dence that GC-dependent asthmatics bind, distribute or 
metabolize GC differently to asthmatics naive to GCs and 
normal subjects (2,7,10). Therefore, one does not need to 
assess GC pharmacokinetics in GC-dependent asthmatics. 
Again, as for acute severe asthma, there is no evidence that 
one compound is better than another at comparable doses. 
Although a twice-daily (8.00 a.m. and 4.00 p.m.) regimen 
has the best anti-inflammatory effect, it is advised to give 
oral GCs once daily or every other day, in the morning (at 
8.00 a.m.), in order to minimize suppression of the circa- 
dian rhythm of the hypothalamic-pituitary-adrenocortical 
system and to reduce the side-effects. Moreover, this 
regimen may improve compliance. In contrast, splitting the 
daily dose of GCs into several small administrations mark- 
edly increases the likelihood of adrenal suppression. The 
effectiveness of the alternate day regimen has not been 
established. As stated above, a high dose of intramuscular 
triamcinolone was found to be more effective than oral 
prednisone (15). However, because of greater steroid side- 
effects with triamcinolone this regimen is not recom- 
mended. The need for prolonged oral GCs should be 
documented by inadequate control despite maximal use of 
other treatment approaches (trigger factor control such as 
allergen avoidance, high dose of inhaled GC, long-acting 
&-agonists and theophyllines) and monitored by diary card 
and pulmonary function tests. A careful monitoring of the 
side-effects should also be performed, comprising a search 
for hypothalamic-pituitary-adrenal axis, bone density 
changes, abnormal glucose metabolism, hypertension, renal 
and ocular side-effects. There is no consensus as to how and 
how often should these tests be performed. GC sparing 
agents have been tried in such patients without any 
dramatic success (19). Trials of dose reduction must be 
constantly attempted. Inhaled GC is beneficial in trying to 
achieve the lowest dose of oral GC needed to control the 
disease (10). The inhaled dose to use is another area of 
uncertainty since 1500 pg did not appear to be more 
effective than 300 pug daily in these patients when symptoms 
and PEF rate were used as outcome parameters (20), but 
further studies are in progress. 
WHAT IS GC RESISTANCE? 
Most patients with asthma respond well to GCs. However a 
handful of patients have little or no change in pulmonary 
function under a GC treatment and thus are classified as 
GC resistant. True GC-resistant asthmatics are rather rare 
(7). A poor response to GCs could be related to abnormal 
absorption, metabolism or a defect in cellular and molecu- 
lar actions. As for corticodependence, there are no clear-cut 
data demonstrating a role for abnormal pharmacokinetics 
in corticoresistance. For example, Schwartz et al. (21) and 
Kamada et al. (22) found a rapid GC clearance (mainly 
cortisol and prednisolone) in 414 adults with CC resistance 
and 13/22 children with poorly controlled asthma respect- 
ively, although Corrigan et al. (23) and Lane et al. (24) did 
not. The molecular mechanisms may be related to an 
abnormal GC receptor binding to either its ligand (e.g. GC) 
or its target (e.g. DNA), the latter being due to an excessive 
expression of the transcription factor AP-1. Further studies 
are in progress in this particular group because the mech- 
anism involved here may give insights into what is happen- 
ing in GC-dependent asthmatics and maybe in asthmatics 
in general. It is not known whether there is any down- 
regulation of GC receptor in the airways with treatment 
with topical GCs. 
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SHOULD EVERY ASTHMATIC BE STARTED ON 
INHALED GC THERAPY? 
The issue of whether inhaled GC should be introduced for 
patients with very mild asymptomatic asthma is still a 
matter of debate. This question and the two following ones 
raise the same concern about the monitoring of asthma 
inflammation. Again, overtreating and undertreating 
asthma may be harmful and markers are needed to give a 
measure of this inflammation. Increasing evidence suggest 
that even in mild asthmatics the airways show evidence of 
inflammation (8,25,26). There is a wide range of patho- 
logical abnormalities and a wide variability among patients. 
Although overall correlations are found between these 
abnormalities and clinical parameters of asthma severity 
and activity, there is a lack of accurate clinically useful tools 
that clearly indicate this fact (27). For example, Wang et al. 
(8) have recently demonstrated in 23 mild asthmatics that 4 
months of beclomethasone dipropionate (BDP) 500 lug 
twice daily led to a significant decrease in endobronchial 
inflammatory markers (GM-CSF, IL-8 and EG2 staining) 
although (only) 7112 BDP-treated patients (versus O/11 
placebo-treated patients) became free of symptoms. Do the 
five mild patients who did not improve clinically under 
BDP treatment need to carry on their inhaled GC treatment 
(maybe at higher dose) and what are the data in the 
literature helping us to convince the seven patients who did 
clinically improve to carry on their inhaled GC treatment? 
Would 2 mg BDP daily be better than this 1 mg daily 
treatment dose? How should we modulate this regimen? 
The usefulness of the blood measurement of ECP has 
mainly been assessed in cross-sectional studies showing its 
relation to asthma severity as measured by FEV, and 
histamine PC,, (27) and to asthma activity as measured 
by peak expiratory flow (PEF) diurnal variations (17). 
Elevated levels of blood ECP seem to identify patients at 
risk of inflammatory exacerbations, maybe representing 
those not optimally treated with inhaled GCs. We need 
more longitudinal studies addressing specifically this 
question. Recently, nitric oxide in exhaled air has been used 
as a non-invasive inflammatory marker of asthma severity 
(28) and its level is inhibited by inhaled GC therapy (29). 
Measurements of inflammatory markers in induced sputum 
are also being evaluated in this regard (30). 
Selroos et al. (31) have recently tried to address the 
question of early versus late introduction of inhalated GCs 
by following during 2 yr 105 consecutive patients with mild 
or moderate asthma not previously treated with inhaled 
GCs. They were using inhaled bronchodilators of three 
or more doses per week and/or they were experiencing 
symptoms during day or night and/or they had PEF or 
FEV, values less than 75% of predicted normal values. 
They were divided into six groups depending on the dura- 
tion of symptoms (~6 months, 6-12 months, l-2 yr, 2-5 yr, 
5-10 yr and >lO yr). They were all given budesonide for 
2 yr (8OOpg daily for most of them) in an open trial. 
Efficacy was evaluated at 3 months, 1 yr and 2 yr by 
measuring FEV, and PEF. The group with asthma 
symptoms that lasted for less than 6 months had the 
greatest improvement in FEV, (+24%). Subjects with 
asthma duration greater than 10 yr when treated with 
inhaled GC for the first time showed a worsening at the end 
of the 2-yr. A previous double-blind randomized parallel 
2 yr study had shown that, when used as regular first-line 
treatment in patients with mild to moderate newly detected 
asthma, budesonide (600,~g twice daily) was significantly 
more effective than inhaled terbutaline (32). Terbutaline- 
treated patients received budesonide (600 pg twice daily) for 
the third year. Significantly poorer clinical improvement 
was seen by comparison with budesonide from the outset 
(33). In a study which followed 278 children with mild to 
moderate asthma treated for 3-6 yr with budesonide, 
Agertoft and Pedersen (34) found that children who started 
inhaled GC early (e.g. within 2 yr after asthma was diag- 
nosed) had a faster and a greater lung function improve- 
ment than others. In addition, the accumulated dose of 
inhaled GCs taken by the former after 4.5 yr of continuous 
treatment was significantly lower than the dose taken by the 
group of children in whom budesonide was not initiated 
until after more than 5 yr of continuous symptoms. These 
results both in adults and in children provide evidence 
that early treatment of symptomatic asthmatics with 
inhaled GCs may prevent the development of chronic 
airflow obstruction and the rapid decline in FEV, of some 
asthmatics. However, the benefits of prescribing inhaled 
GCs at the first diagnosis of asthma to all patients 
would require evaluation in a large international 
placebo-controlled trial. 
WHAT IS THE AMOUNT OF INHALED GC 
REQUIRED AND FOR HOW LONG? 
The question of how much and for how long inhaled GCs 
should be used for the mild asthmatics will not be answered 
before we identify markers of airway inflammation that 
correlate with progression of asthma. The use of 2 mg daily 
of BDP leads to a better control of asthma symptoms than 
lower doses. It is worth mentioning that the clinical dose- 
response relationship is a rather shallow one such that, for 
example, there was not much difference in effect on bron- 
chial responsiveness between 400 and 800,~g daily of 
budesonide. Boe et al. (35) did not find any statistically 
significant differences between the effect of daily doses of 
400-800 pg daily of budesonide or between 400 and 1000 pug 
daily of BDP on PEF and diary recordings. Dale et al. (36) 
found very similar results using lOO-8OOpg daily of 
fluticasone propionate in 672 patients. No formal dose- 
response studies have been performed in pre-school 
children, so that the optimal dose in this age group is not 
known. In school chidren, 200-8OOpg daily from a spacer 
and lOOO-2OOOpg daily of budesonide from a nebulizer 
have been shown to be roughly equivalent (37,38). Further- 
more, there is no published evidence that increasing the 
dose above 2 mg daily in adults increases the beneficial 
response (39). It is advocated that starting with a relatively 
high dose of inhaled GC first to gain rapid control of the 
asthma is a better policy with the dose reduced gradually to 
a minimum afterwards. When asthma worsens, the dose 
of GC can be temporarily doubled until control is 
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re-established although there is no good evidence so far to 
indicate the efficacy of this approach. How long a patient 
should remain on GC therapy once the disease is controlled 
is not known. However, it is clear that, on discontinuing 
treatment, asthmatics do worsen after a variable period of 
time. 
One issue that is discussed a lot is that of the poten- 
tial systemic dose-dependent side-effects of long-term 
treatment, particularly the potential for blocking the 
hypothalamic-pituitary-adrenal axis and inducing osteo- 
porosis. Our experience with inhaled GCs so far is that 
these problems are unlikely to be of clinical importance 
although, in some susceptible patients, clinically significant 
side-effects may be a problem. For patients for whom 
currently available inhaled GCs are incompletely effective 
prolonged oral GCs should be considered with the limita- 
tions described above. Use of other anti-asthmatic drugs 
should also be considered. The combination of inhaled GC 
with long-acting &agonists indicates that doubling the 
dose of GC does not provide any benefit while the addition 
of a long-acting &agonist to a low-dose GC treatment has 
additive effects. Other agents that may be worth considering 
in combination with low-dose GC include theophylline, 
particularly at low dose. Such a combination may be more 
important for patients needing high-dose GC for asthma 
control or for patients with poorly controlled asthma 
even when using high-dose inhaled GCs. Recently, Busse 
et al. (40) have shown that azelastine 6 mg twice daily 
was able to reduce significantly the daily inhalations of GC 
in a 12 week double-blind trial, without deterioration of 
lung function. 
DOES ONE INHALED GC PROVIDE MAJOR 
THERAPEUTIC ADVANTAGE OVER OTHERS? 
Inhaled GCs have different affinities for their cellu- 
lar receptor and variable pharmacokinetic parameters 
(Table 3). The search for even more potent GCs than the 
ones currently available now continues. One wonders who 
much further breakthrough there will be as it appears 
difficult to devise a molecule that would be very active and 
not absorbed from the airway submucosa where the GC has 
to get to in order to effect its beneficial actions. In addition, 
it is not known whether a more potent GC would 
provide improved benefits given the shallow dose-response 
relationship of current GC at moderate and high dosages. 
HOW SHOULD INHALED GC THERAPY BE 
SCHEDULED DURING THE DAY TO OPTIMIZE 
THE TREATMENT? 
Initially, inhaled GC was given four times per day. It has 
since been shown that twice-daily regimens may be as 
effective as four times daily ones (41) but even this issue is 
the subject of controversy. Thus, Malo et al. (42) have 
recently demonstrated in a randomized parallel 6-12 
months study that administering inhaled budesonide with a 
Turbuhalera device four times per day resulted in fewer 
‘flare-ups’ in spite of less compliance and more frequent 
local side-effects than on a twice-daily regimen basis at daily 
doses of 800 and 12OOpg. In order to improve compliance, 
once-daily regimens have been tested with conflicting 
results in a relatively short duration of follow-up (34 
weeks). In a 12 month follow-up, double-blind, randomized 
study, Weiner et al. (43) have recently found in 40 moderate 
asthmatic patients that 4OOpg of budesonide twice daily 
(morning and bedtime) is more effective than a single dose 
of 8OOpg at bedtime (in terms of number of &agonist 
inhalations, PEF variability and asthma symptom scores). 
WHAT ARE THE PHARMACOKINETIC DATA 
AVAILABLE? 
Pharmacokinetic data after inhalation are limited and can 
hardly be used as a criteria for selection of therapy. 
Concerning budesonide with a Turbuhale@, for example, 
it has been shown in ten healthy volunteers using radio- 
labelled particles that lung deposition varies from 
14.8 f 3.3% to 27.7 i 9.5% according to the inhalation flow 
(from a slow flow of 36 1 min - i to a normal flow of 
581min-’ respectively (44). Concentrations in blood 
plasma are 1/8th of that in lung tissue (45). GCs are mostly 
active locally, as shown by Toogood et al. (46). Absorption 
of the swallowed fraction is usually largely metabolized to 
inactive metabolites in the liver (first-pass metabolism). 
Thus, the degree of first-pass metabolism and the amount 
absorbed from the airways (which is in turn dependent on 
the delivery system used and the efficacy with which it is 
used) determine to a large extent the potential for systemic 
side-effects. Mouth rinsing employed after using a spray 
reduces gut availability and obviates local adverse effects. 
When high doses are required for asthma control, the GC 
with the lowest bioavailability should be chosen (Table 3). 
One issue that is unclear is whether there is any devel- 
opment of ‘tachyphylaxis’ to the actions of GCs by 
GC-induced receptor downregulation or other mechanisms. 
WHAT IS THE COST-EFFECTIVENESS OF 
INHALED GCs? 
Long-term use of inhaled GCs has been shown to reduce 
inpatient hospital admissions and cost of care [in 36 
budesonide-treated patients followed during 5 yr (47)]. In a 
2.5 yr randomized controlled study in 274 patients, 
Rutten-van Mollen et al. (48) concluded that the addition 
of an inhaled GC to a &-agonist leads to significant benefits 
in FEV,, PC,,, restricted activity days and symptom-free 
days with relatively low additional health care costs ($201 
per patient per year). Inhaled GCs have also been found to 
be cost-effective in pre-school (49) and school (34) children. 
Using budesonide to treat symptomatic children with 
asthma, aged l-3 years, increased symptom-free days com- 
pared with placebo and reduced overall costs by $9.5 per 
symptom-free day gained (50). 
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Conclusion 
Thus GCs are the best medicines available at present to 
improve the clinical status and many of the underlying 
physiological abnormalities of most asthmatics. The rela- 
tive safety of topical (inhaled) formulations has led to 
recommendations that GCs may be used more aggressively 
than in the past, as early as possible and for as long as 
possible in symptomatic asthmatics, with the goal of con- 
trolling asthma symptoms. There may be long-term 
beneficial effects. In the guidelines, a frequency of 
&-agonist use of more than three times per week is an 
indication for initiating inhaled GC therapy. There are, 
however, very few studies evaluating the outcome of these 
recommendations. In this paper the available data on GC 
pharmacology have been analysed and crucial unresolved 
issues have been highlighted. The asthmatic patient often 
has a distrust of GC therapy and the process of convincing 
the patient of the benefits of GC therapy is part and parcel 
of the management of the asthmatic, as is demonstrating 
to the patient the correct use of his or her inhaler since 
around 50% of our patients are either non-compliant or 
misusers (49). 
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